Loading
companiesCompany
Isabl
Isabl reads a tumour's whole genome and transcriptome instead of a small gene panel, and its software turns that into a report clinicians can use.
Overview
Isabl, a Memorial Sloan Kettering spin-out, provides software and a CLIA laboratory for clinical whole-genome and whole-transcriptome sequencing of tumours, analysing the full range of mutations, structural variants, signatures and expression rather than a targeted panel, with applications in treatment planning, disease surveillance and biomarker discovery. It states it is the first to receive New York State approval for a whole-genome and transcriptome cancer test. Evidence of clinical utility beyond analytical validation is still accumulating.
Headquarters
New York, NY, US
Funding
All startupsStartupYC W20
Investors
Type
Stage
Startup · Y Combinator Winter 2020
Website
Similar pages
- CompanyOncobox
Shares Y Combinator, RNA sequencing & expression profiling and the tag yc.
- CompanyBlank Bio
Shares Y Combinator, RNA sequencing & expression profiling and the tag yc.
- CompanyData Driven Bioscience (Duoseq)
Shares Y Combinator, RNA sequencing & expression profiling and the tag yc.
- CompanyBillionToOne
Shares Y Combinator, MRD / molecular residual disease testing and the tag yc.
- CompanyArpeggio Bio
Shares Y Combinator, RNA sequencing & expression profiling and the tag yc.
- CompanyCofactor Genomics
Shares Y Combinator, RNA sequencing & expression profiling and the tag yc.
- CompanyAluna
Shares Y Combinator and the tag yc.
- CompanyMednet (theMednet)
Shares Y Combinator and the tag yc.